Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Homayoon Khanlou"'
Autor:
Homayoon Khanlou, Robert Corales, Frank Rhame, Daniel J. Skiest, Thanes Vanig, Karam Mounzer, Nicholaos C. Bellos, Edwin DeJesus, Calvin J. Cohen, Hannah Olivet, Andrew E. Petroll, Marc Tribble, Jane Garb
Publikováno v:
HIV & AIDS Review. 11:77-83
Objectives To determine if switching virologically suppressed patients on a regimen containing lopinavir/r (LPV/r) or fosamprenavir (FPV/r) to darunavir/r (DRV/r) or atazanavir/r (ATV/r) results in improved TGs while maintaining virological suppressi
Autor:
Albrecht Stoehr, E Lefebvre, Frank Tomaka, E Lathouwers, Khuanchai Supparatpinyo, Homayoon Khanlou, M Opsomer, Chloe Orkin, Edwin DeJesus, T Van De Casteele
Publikováno v:
HIV Medicine. 14:49-59
Objective This paper presents the final analysis of once-daily darunavir/ritonavir (DRV/r) vs. lopinavir/ritonavir (LPV/r) in treatment-naive HIV-1-infected adults. Methods ARTEMIS (AntiRetroviral Therapy with TMC114 ExaMined In naive Subjects; NCT00
Autor:
Belinda Ha, Anthony Scarsella, Keith A. Pappa, Homayoon Khanlou, Winston Young, Henry Zhao, Franco Felizarta, Lisa Ross
Publikováno v:
World Journal of AIDS. :24-32
Background: Managing hypertriglyceridemia in HIV-infected patients often requires multiple pharmacologic strategies. Many protease inhibitors (PIs), one of 6 classes of drugs used to treat HIV, have been associated with hypercholesterolemia and drug
Autor:
Eric S. Daar, Homayoon Khanlou, Douglas Frye, Rhodri Dierst-Davies, Judith Tejero, William J. Towner, Amy Rock Wohl, Joseph Cadden, Juli-Ann Carlos
Publikováno v:
AIDS Patient Care and STDs. 25:525-532
HIV-infected patients frequently experience depression, drug use, and unstable housing but are often unable to access supportive services to manage these challenges. Data on barriers to needed supportive services are critical to improving patient acc
Autor:
Shilpa Sayana, Homayoon Khanlou
Publikováno v:
Future HIV Therapy. 2:125-136
Darunavir (formerly known as TMC 114) is a protease inhibitor that was approved by the US FDA in June 2006 for use in treatment-experienced patients, with markedly greater virological and immunological benefits compared with the standard of care. It
Publikováno v:
Journal of the International Association of Physicians in AIDS Care. 10:135-137
The development of newer agents such as raltegravir, etravirine and maraviroc has improved the perspective of viral load suppression. However, there is not enough data regarding their use together. In this study, we describe nine patients who were tr
Publikováno v:
AIDS research and human retroviruses, vol 30, iss 10
A putative source of inappropriate immune activation that drives human immunodeficiency virus (HIV)-1 immunopathogenesis is the gastrointestinal tract. Even with effective antiretroviral treatment, residual activation persists. We hypothesized that a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7d02ab0032e1b6f3dc974440aacb352
https://europepmc.org/articles/PMC6461151/
https://europepmc.org/articles/PMC6461151/
Autor:
Homayoon Khanlou, Shilpa Sayana
Publikováno v:
Journal of the International Association of Physicians in AIDS Care. 7:289-291
Meningitis due to methicillin-resistant Staphylococcus aureus is a rare clinical presentation but has been well documented in postneurosurgical patients. To our knowledge, no case of methicillin-resistant Staphylococcus aureus meningitis has been pre
Publikováno v:
AIDS and behavior. 17(8)
This retrospective cohort study examined electronic medical records of HIV-positive patients in California (N = 7,834) to find the prevalence of any psychiatric condition and the associations between several factors and the likelihood of these disord
Autor:
R Corales, Homayoon Khanlou, T Vanig, J Appelbaum, C Cohen, W Burman, M Tribble, Jane Garb, Edwin DeJesus, H Olivet, J Green, D Sweet, G Pierone
Publikováno v:
Journal of the International AIDS Society. 15
Patients virologically suppressed on TDF/FTC + ATV/r may require alternative regimens that maintain suppression while addressing some drug-related side effects. We explored two alternative regimens that replace RTV and/or TDF/FTC. This open-label exp